阿齐沙坦酯治疗原发性高血压安全性和有效性的Meta分析

Safety and efficacy of azilsartan medoxomil in the treatment of primary hypertension:a Meta-analysis

目的:评价阿齐沙坦酯(azilsartan medoxomil,AZL-M)治疗原发性高血压的安全性及有效性。方法:检索PubMed、Embase、Cochrane、Web of Science、中国知网、万方、维普等数据库中关于阿齐沙坦酯治疗原发性高血压的随机对照试验,筛选符合纳入标准的文献并进行文献质量评价,采用RevMan 5.3软件进行Meta分析。结果:共纳入8篇RCT,6148例患者。阿齐沙坦酯治疗组不良事件的发生率无显著性差异(OR=1.03,95%CI:0.94~1.14,P=0.51),导致停药的不良事件发生率也无显著性差异(OR=1.09,95%CI:0.84~1.41,P=0.52)。与其他药物相比,阿齐沙坦酯治疗有更高的收缩压响应率(OR=1.34,95%CI:1.02~1.74,P<0.00001)和血压响应率(OR=2.2,95%CI:1.82~2.66,P<0.00001)。结论:阿齐沙坦酯治疗原发性高血压疗效显著,且不良反应事件的发生率与其他现有治疗药物相当。

Objective:To evaluate the safety and efficacy of azilsartan medoxomil(AZL-M)in the treatment of primary hypertension.Methods:Randomized controlled trials of azilsartan medoxomil for treating primary hypertension were searched in PubMed,Embase,Cochrane,Web of Science,CNKI,Wangfang and VIP databases.The Jadad scale was used to assess quality of the included trials and RevMan 5.3 software was used for Meta-analysis.Results:Eight RCTs,including 6148 patients,were enrolled in this study.There was no significant difference in the incidence of adverse events(AEs)among AZL-M and other drugs for hypertension(OR=1.03,95%CI:0.94~1.14,P=0.51),either the rate of AEs leading to discontinuation(OR=1.09,95%CI:0.84~1.41,P=0.52).Compared with other drugs,AZL-M showed a better improvement in response rate of systolic blood pressure(OR=1.34,95%CI:1.02~1.74,P<0.00001)and blood pressure(OR=2.2,95%CI:1.82~2.66,P<0.00001).Conclusion:AZL-M has a significant clinical efficacy and a comparable safety in treating primary hypertension.